Here we demonstrate that HRT-induced immunity and enhanced SIRPα expression together provide a window of opportunity for the potent pharmacological effects of SIRPα inhibitors, reducing HRT resistance in CRC and increasing the rate of HRT-induced immune response. The gene discussed is SIRPA; the disease is colorectal carcinoma.